Efficacy of different therapeutic options for pain relief and treatment of burning mouth syndrome: a systematic review
- 6 November 2025
- journal article
- review article
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (11) , 1-20
Abstract
Objectives This study aimed to evaluate the efficacy of different therapeutic options currently used to treat and relieve the pain of Burning Mouth Syndrome (BMS), in order to provide better clinical guidance for future practice. Materials and methods A systematic qualitative synthesis of randomized controlled trials (RCTs) was conducted, grouping evidence by intervention type. Twenty-one RCTs were included, assessing pharmacological, topical, systemic, physical, and combined interventions. Studies were selected if they directly evaluated treatments in patients diagnosed with BMS; non-randomized trials were excluded. Electronic searches were performed in PubMed, Google Scholar, and Scielo using the MeSH terms: “Burning Mouth Syndrome,” “Oral Burning,” “Treatment,” and “Randomized Controlled Trial.” Outcomes focused on symptom relief, adverse effects, and comparisons with placebo or other treatments. Methodological quality was assessed using risk of bias criteria. Data extraction followed a systematic, cross-validated protocol. Due to substantial clinical and methodological heterogeneity, only a qualitative synthesis was performed. Results Fourteen interventions were identified, including alpha-lipoic acid, topical/systemic clonazepam, low-level laser therapy (LLLT), capsaicin, melatonin, gabapentin, and cognitive-behavioral therapy. Topical clonazepam, alpha-lipoic acid, and LLLT consistently demonstrated the most significant symptom improvement with few mild adverse effects. Conclusions While topical clonazepam, alpha-lipoic acid, and low-level laser therapy (LLLT) emerged as potentially effective options in several RCTs, the overall strength of evidence is limited. These therapies appear promising, but further high-quality, larger randomized trials are needed before firm first-line recommendations can be made. Clinical relevance This study provides evidence-based guidance for clinicians in selecting effective treatments for BMS, emphasizing tailored therapeutic approaches and the potential benefits of topical clonazepam, alpha-lipoic acid, and low-level laser therapy as first-line options.Keywords
This publication has 29 references indexed in Scilit:
- Efficacy of 660 nm Photobiomodulation in Burning Mouth Syndrome Management: A Single-Blind Quasi-Experimental Controlled Clinical TrialPhotobiomodulation, Photomedicine, and Laser Surgery, 2024
- Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trialClinical Oral Investigations, 2018
- Evaluation of laser therapy and alpha-lipoic acid for the treatment of burning mouth syndrome: a randomized clinical trialLasers in Medical Science, 2018
- Analgesic effect of topical oral capsaicin gel in burning mouth syndromeActa Odontologica Scandinavica, 2016
- The Efficacy of Daily Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for Burning Mouth Syndrome (BMS): A Randomized Controlled Single-blind StudyBrain Stimulation, 2016
- A randomized pilot study to assess the safety and the value of low-level laser therapy versus clonazepam in patients with burning mouth syndromeLasers in Medical Science, 2016
- Burning mouth syndrome in Parkinson’s disease: dopamine as cure or cause?The Journal of Headache and Pain, 2012
- Trigeminal small-fiber sensory neuropathy causes burning mouth syndromePain, 2005
- Interventions for the treatment of burning mouth syndrome2005
- Sensory dysfunction in burning mouth syndromePain, 2002